Parkinson's disease

Medical marijuana update: Top 3 things health execs should knowHere’s what you need to know about medical marijuana laws, and what they mean for the healthcare system.
Safinamide (Xadago): Approved as Add-On for Parkinson’sXadago has been approved as a supplementary medication for patients with Parkinson's disease who are having "off" episodes or whose disease is progressing.
Researchers image single cell deaths in glaucoma patientsA new imaging technique can show the deaths of individual cells in people with glaucoma by labelling the cells with fluorescent dye, according to researchers. The approach might eventually be used to diagnosis the disease in its early stages or measure its progression.
9 Newly Approved Novel Drugs
9 Newly Approved Novel DrugsIt's still early in 2017, but the FDA has been approving drugs left and right. Here's what you need to know.
New Parkinson's drug, 2 others approvedFDA approved safinamide (Xadago, Newron Pharmaceuticals) tablets as an add-on treatment for patients with Parkinson’s disease. FDA also approved new treatments for classical Hodgkin lymphoma and pemphigus vulgaris, a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.
Key cogs in the management of Parkinson’s disease
Key cogs in the management of Parkinson’s diseaseThe goal of this activity is to assist pharmacists in managing difficult-to-treat symptoms of Parkinson’s disease.
First drug approved for hallucinations in Parkinson’sFDA approved the first drug to hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease.
Diabetes drug may reduce Parkinson’s incidenceDiabetes patients taking rosiglitazone or pioglitazone had a 28 percent lower incidence of Parkinson's disease (PD) than people taking other treatments for diabetes who had never taken the glitazone (GTZ) drugs, according to a new study.
Parkinson’s disease: Unmet needs to be fulfilled by novel therapies and reformulationsThe current global Parkinson’s disease market is characterized by a number of unmet needs, which include addressing the motor complications of dyskinesia and off-episodes. The recent approval of novel therapies and reformulations of existing drugs has the potential to fulfill some of these unmet needs, particularly in patients with advanced disease.
First-in-class therapy promising for Parkinson's disease psychosisA first-in-class antipsychotic that is a selective serotonin inverse agonist (with no dopaminergic, histaminergic, adrenergic, or muscarinic activity) potentially targeting 5-HT2A receptors, improved Parkinson’s disease psychosis (PDP) with demonstrated safety and tolerability, and without worsening motor Parkinson’s, according to data presented in two posters at the 19th International Congress of Parkinson’s Disease and Movement Disorders (MDS), in San Diego.